You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
SBC: NEWVENTUREIQ LLC Topic: 102Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeted ColQ gene therapy for Congenital Myasthenic Syndromes
SBC: Amplo Biotechnology, Inc. Topic: 106PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Automating Assessment of Contextualization of Care During the Clinical Encounter
SBC: Institute for Practice and Provider Performance Improvement, Inc. Topic: 600Background: Large scale studies have demonstrated that when patients struggle with life challenges that complicate their care (e.g., a lack of social support, competing responsibilities, or financial hardships), health care providers can improve health care outcomes and lower costs if they attempt to identify these “contextual factors” and address them in their care plan – a process termed ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Inducible HMGB1 antagonist for viral-induced acute lung injury.
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NHLBIFor more than a decade, our work has focused on development of therapeutic interventions for viral- and bacterial-induced acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS). Significantly, we identified the Toll-like receptor 4 (TLR4) signaling pathway as key to the host response to influenza and secondary bacterial infection following influenza. We also identif ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a portable beat-to-beat fetal ECG system
SBC: AUSCULTECH DX LLC Topic: NICHDProject Summary There are 24,000 stillbirths per year in the United States, and 2.6 million stillbirths per year worldwide, with no significant decrease in the last decade. Abnormal fetal heart rhythms, such as long QT syndrome, are thought to play an important role in these deaths, and may cause 3- 10% of unexplained stillbirths. This is in addition to known fetal arrhythmias, which affect 1-3% o ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Motion-Resistant Background Subtraction Angiography with Deep Learning:Real-Time, Edge Hardware Implementation and Product Development
SBC: CLEARVOYA LLC Topic: NHLBICatheter Digital Subtraction Angiography (DSA) is an imaging technique that was developed in the 1980s to allow physicians to visualize blood vessels. Today, this technology is utilized for minimally-invasive interventions that treat numerous devastating pathologies, including stroke and myocardial infarction, diseases that disproportionally impact underserved minority patient populations.Catheter ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection
SBC: Covira Surgical Topic: NIAIDSUMMARY Covira Surgical, Inc. is developing CS-0003, a first-in-class, orally administered non-antibiotic therapy for preventing infections in patients undergoing gastrointestinal (GI) surgeries. Despite improved surgical procedures, broad use of antibiotics, mandated asepsis measures, and enhanced recovery programs, post-surgical infections remain a clear and present danger to patients. Surgical ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
SMALL MOLECULE THERAPEUTIC FOR ALZHEIMER'S DISEASE
SBC: SOMATOLYNK, INC. Topic: NIAAn estimated one out of eight individuals over the age of 65 has Alzheimer’s disease (AD), with a prevalence of 1-in-3 for those over age 85. There are approximately 5.8 million people in the USA with AD, with a global projection of over 150 million by 2050. There remains a lack of effective treatment to halt disease progression. Somatostatin receptor-4 (SSTR4) represents an innovative and viabl ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
An immunotherapeutic IgY formulation against norovirus diarrhea
SBC: SCALED MICROBIOMICS LLC Topic: NIAIDProject Summary/Abstract for STTR Phase I Application: An immunotherapeutic IgY formulation against norovirus diarrhea Human norovirus (HuNoV) infects millions of people globally each year, causing diarrheal illness resulting in more than 200,000 deaths annually, particularly in the very young, the very old, and the immunocompromised. There is currently neither an effective vaccine nor effective t ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
SBC: Axioforce LLC Topic: NIBIBPROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health